Lung cancer is a major cause of cancer-related mortality worldwide 1 . Histologically, lung cancer is usually classified as small cell or non-small cell lung cancer (NSCLC) and the latter represents up to 85% of all lung cancer cases and frequently is diagnosed at the later stages of disease, preventing curative surgery. Platinum-based chemotherapy is the first line standard treatment for NSCLC patients with advanced disease 2 ; however, such treatment is often associated with poor response due to drug resistance. Chemotherapy resistance of NSCLC to platinum-based treatments is complex, but single-nucleotide polymorphisms (SNP) in apoptosis genes, particularly the BCL2 family, may play a critical role 3 . Platinum-based chemotherapeutic agents bind to and cause crosslinking of genomic DNA, especially in fast growing tumor cells, and trigger tumor cells to undergo apoptosis 4 . Apoptosis is a process of programmed cell death that occurs under both physiological and pathological conditions.
Apoptosis regulates homeostasis in the human body. The balance of anti-apoptotic and pro-apoptotic proteins determines cell fate and regulates the response to apoptotic signals [5] [6] [7] . Deficiency in apoptosis alters intracellular homeostasis and may lead to carcinogenesis and promote tumor progression 8 . Two well-characterized regulators of apoptosis are the anti-apoptotic B-cell lymphoma 2 (BCL2) and the pro-apoptotic B-cell lymphoma 2-associated X protein (BAX ). BCL2 promotes cell survival by inhibiting apoptosis, whereas BAX promotes apoptosis 9, 10 . Thus, aberrant expression of Bcl-2 and/or BAX is thought to play a role in cancer development. Additionally, SNPs in these genes have been reported to be associated with various human cancers such as head and neck squamous cell carcinoma 11 , endometrial cancer 12 , prostate cancer 13 , breast cancer 14 , acute lymphoblastic leukemia 15 and glioma 16 . Furthermore, high BCL2 expression has been associated with chemoresistance, and overexpression in cell lines has been observed to inhibit apoptosis 17, 18 . Crosstalk occurs between chemotherapy-induced DNA damage and mitochondrial-induced apoptosis 19 . Previous studies have indicated that BCL2 and BAX SNPs are associated with survival in various types of cancer [20] [21] [22] [23] [24] [25] [26] . Most studies of BCL2 and BAX SNPs have focused on the promoter regions of these two genes, BCL2-938C> A (rs2279115) and BAX-248G> A(rs4645878), because they have been reported to be associated with altered expression of BCL2 and BAX 14, 25, 27 . The BCL2-938C> A A allele was associated with an increase in BCL-2 expression [14, 27] . The BAX-248G> A A allele was associated with a decrease in BAX expression 25 . Hence, in this study, we hypothesized that BCL2 and BAX polymorphisms, located in the untranslated promoter regions, could be associated with treatment responses and clinical outcomes in advanced NSCLC treated with platinum-based chemotherapy. To assess our hypothesis, we analyzed the responses and treatment outcomes of 235 patients with advanced NSCLC treated with platinum-based therapy and the association of treatment response and outcomes with BCL2 -938C> A) (rs2279115) and BAX -248G> A (rs4645878) SNP status.
Material and Methods
Study Population, Response Assessment, Toxicity Evaluation and Survival Calculation. In this study, we enrolled a total of 235 inoperable NSCLC (stage III/IV) patients treated with at least two cycles of first line platinum-based chemotherapy between July 2007 and July 2012 from Daping Hospital, The Third Military Medical University (Chongqing, China). The study was approved by the ethics committee of the Daping Hospital and also carried out according to the protocols approved by the ethics committee. Only patients who understood the purpose of the study and signed the informed consent were included in the study. All patients had routine blood, hepatic and renal function tests, and an electrocardiogram. Patients had not received previous chemotherapy or radiotherapy and also had no other malignancies in the 5 years preceding this study. Patients were assessed for their Eastern Cooperative Oncology Group performance status (ECOG PS) and all participants were graded as level 0 ~ 2 before chemotherapy. Patients were treated with 75 mg/m 2 cisplatin on day 1 plus 135 mg/m 2 Taxol, 75 mg/m 2 docetaxel, or 1000 mg/m 2 gemcitabine on day 1 and day 8. The therapy cycles were repeated every 3-4 weeks.
Standard Response Evaluation Criteria in Solid Tumors (RECIST 1.0) were used to evaluate the treatment response, and the response was assessed by comparison of the baseline MRI or CT images with the follow-up images after every two cycles of chemotherapy. Patients were categorized as responders (complete response and partial response; CR or PR) or nonresponders (stable disease and progressive disease; SD or PD).
Chemotherapy-related toxicities were recorded for each treatment cycle, including leukocytopenia, anemia, thrombocytopenia, nausea, vomiting, diarrhea, neuropathy, weakness, hypersensitivity reaction, and renal toxic effects. Grade 3/4 toxicity (defined by the National Cancer Institute common toxicity criteria version 3.0) was assessed twice a week during chemotherapy.Progression-free survival (PFS) was calculated from the start of treatment to documentation of the first date of disease progression (death was considered a progression event in patients who died before disease progression). Overall survival (OS) was calculated from the start of treatment to death. Patients without documented death or objective progression at the time of the final analysis were censored at the time of their last objective tumor assessment or at the date they were last known to be alive. The survival data in this study were censored on July 23, 2014. Ten (4.3%) cases were censored.
Genotyping. A 5 mL whole-blood sample was obtained from each patient before chemotherapy.
Genotyping of BCL2-938C>
A SNPs and BAX-248G> A was conducted by using the PCR-restriction fragment length polymorphism (PCR-RFLP) method. Each PCR amplification was performed in a 25 μ l reaction mixture containing 12.5 pmol of each primer, 2 μ l genomic DNA, 0.5 U of TaqMan SNP Genotyping Assay Mix (40x), 0.30 mM of dNTPs, 1.5 mM total MgCl 2 , and 5 μ l of PCR buffer (5×).
The primers used to detect the BCL2-938C> A polymorphism were 5′ -CTGCCTTCATTT ATCCAGCA-3′ and 5′ -GGCGGCAGATGAATTACAA-3′ 11 The primers for the BAX-248G> A polymorphism were 5′ -CGGGGTTATCTCTTGGGC-3′ and 5′ -GTGAGAGCCCCGCTGAAC-3′ ' 28 . The PCR conditions consisted of an initial denaturation at 95 °C for 5 min, followed by 40 cycles of 30 s at 94 °C, 30 s at 56 °C, and 45 s at 72 °C and a final extension at 72 °C for 5 min. The PCR products were then digested by Aci I (Aci I, which recognizes CCGC, New England BioLabs) at 37 °C for 15 min. Homozygous GG alleles (wild-type) were visualized as three major bands of 352, 256, and 96 base pair (bp) with the highest intensity for the 256-bp band under the UV light. In the heterozygous condition (AG alleles) the 256bp and 96 bp products are fainter, while the 352bp band is more intense. In contrast, the homozygous AA alleles (homozygous carrier of this SNP) showed only one 352-bp band.
Statistical Analyses. Statistical analyses were performed using SPSS (IBM SPSS Statistics 19, SPSS, Chicago, IL, USA). Differences in response to treatment or grade 3/4 toxicities were analyzed between groups with different genotypes of these SNPs (variants vs. the wild-type) by calculation of p values using the Pearson χ 2 test or the Fisher exact test. Multivariate logistic regression analyses were used to assess associations between the selected SNPs and chemotherapy response or toxicity by estimating odds ratios (ORs) and 95% confidence intervals (CIs). Survival curves for PFS and OS were determined using the Kaplan-Meier method and the Log-rank test was used to generate p values. Multivariate Cox proportional hazards models (Forward Stepwise: Likelihood Ratio) were used to estimate adjusted hazard ratios (HR) with 95% confidence intervals. Multivariable regressions analysis was adjusted for age, gender, ECOG stage, histology, disease stage, smoking status, weight loss, and chemotherapy regimens. Two-sided p-values of less than 0.05 were considered statistically significant. In order to adjust the p-value due to multiple comparisons, the Bonferroni-Holm method was used to calculate the p-value for the results of any SNP.
Results

Patient characteristics.
Patients' characteristics and genotypic data are shown in Table 2) .
For chemotherapy, 180 (76.6%) patients received TP regimens (Taxol/docetaxel plus cisplatin), 32 (13.6%) had GP regimens (gemcitabine plus cisplatin), and 23 (9.80%) had other platinum combinations (vinorelbine plus cisplatin or pemetrexed plus cisplatin). The median number of chemotherapy cycles was four (range between 2 and 8).
Association of Genotypes with Treatment Response and Toxicity. The overall response rate of patients to platinum-based chemotherapy was 35.7% with the following responses to the first-line treatments: one patient had CR (0.4% of evaluable patients), 83 PR (35.32%), 75 SD (31.9%), and 76 PD (32.3%). A numerically increased rate of response was observed in patients with the BAX-248GG vs. the GA or GA+ AA phenotype but the differences did not reach statistical significance after multiplicity adjustment (42.6% vs. 27.6%, p = 0.024; 42.6% vs. 27.4%, p = 0.015). No statistically significant association was observed between BCL2-938C> A and responses to chemotherapy (Table 3) . After adjusting for age, gender, ECOG PS, histology, tumor stage, smoking status, chemotherapy regimens, weight loss, BCL2-938C> A, and BAX-248G> A, the logistic regression model analysis showed that the following parameters were able to predict the treatment response: ECOG PS (adjusted OR 2.112, 95% CI 1.156-3.857, p = 0.015), tumor stage (adjusted OR 2.887, 95% CI 1.510-5.518, p = 0.001), smoking status (adjusted OR 2.446, 95% CI 1.140-5.247, p = 0.022) and BAX-248G> A (GG vs. GA, adjusted OR 1.943, 95% CI 1.035-3.648, p = 0.039; GG vs. GA+ AA, adjusted OR 1.867, 95% CI 1.035-3.369, p = 0.038).
The incidence of grade 3/4 toxicity was 57.5%. In particular, 90 patients (38.3%) had grade 3/4 hematologic toxicity, 44 patients (18.7%) had grade 3/4 gastrointestinal toxicity, 27 patients (11.49%) had both and 127 patients (54.04%) had neither hematologic toxicity nor gastrointestinal toxicity. Our SNP data showed that there was no significant association between risk of grade 3/4 hematologic toxicity or gastrointestinal toxicity and BCL2-938C> A (adjusted OR Association of Genotypes with PFS and OS of these patients after chemotherapy. The median follow-up time was 22 months (range between 1.8 and 70.4 months) and 214 (91.06%) patients died during the follow-up. The one-year survival rate was 60% and the 2-year survival rate was 25%. The median PFS was 7.0 months (95% CI, 6.058-7.942). The median OS was 15.0 months (95% CI, 12.981-17.019).
In univariate analysis, patients with BCL2-938AA, CA or CA+ AA genotype had significantly shorter median PFS compared with those with − 938CC genotype [9 m vs. 5 m, p = 0.035 (the difference did not reach statistical significance after multiplicity adjustment); 9 m vs. 6 m, p = 0.004; 9 m vs. 6 m, p = 0.003; Log-rank test; respectively; Fig. 1a (Table 4) .
Furthermore, in the univariate model ( After that, we combined these two BCL2-938C> A and BAX-248G> A polymorphisms for association with PFS and OS of patients. Our data showed that the -938A and -248A were classified as adverse alleles based on association with higher risk of progression and death presented in Table 4 and as the number of adverse allele increased, the median PFS and OS decreased. Patients with more than 2 adverse alleles had shorter median PFS (5 m vs. 8 m, p = 0.001) and OS (12 m vs. 18 m, p < 0.001) compared to those with 0-1 adverse alleles (Table 4 , Fig. 2. tif) . The multivariate analysis showed that patients with 2-4 adverse alleles had an increased risk of disease progression (HR 1.637, 95% CI 1.240 ~ 2.161, p = 0.001) and death (HR 2.365, 95% CI 1.760-3.178, p < 0.001). These significances remained after the Bonferroni-Holm method analysis.
Discussion
Cisplatin resistance occurs through a variety of mechanisms, such as changes in cellular uptake and efflux of the drug, increased expression of detoxification enzymes, increased DNA repair or inhibition of apoptosis 29 . In this study, we investigated whether the occurrence of SNPs, located in the promoter regions of two apoptosis-related genes are associated with responses and/or outcomes in patients with advanced NSCLC that are treated with cisplatin-based chemotherapy. A numerically increased rate of response was observed in patients with the BAX-248GG vs. the GA or GA+ AA phenotype but the difference did not reach statistical significance after multiplicity adjustment. We found no significant association between the BCL2-938C> A polymorphism and chemotherapy response. There was no statistical association between BCL2-938C/A or BAX-248G> A polymorphism and grade 3/4 hematologic or gastrointestinal toxicity in these patients. Furthermore, patients with the BCL2-938C> A variant genotype (A allele) or BAX-248G> A variant genotype (A allele) associated with poor PFS and OS. The combined BCL2-938C> A and BAX-248G> A were also associated with PFS and OS of the patients. The multivariate analysis showed that ECOG PS, BCL2-938C> A, and BAX-248G> A were all independent predictors for OS of these NSCLC patients. To the best of our knowledge, this is the first study of this kind to demonstrate an association between the BAX-248G> A or the combination of BCL2-938C> A and BAX-248G> A with outcome of advanced NSCLC patients to cisplatin-based chemotherapy.
BCL2 is localized to chromosome 18q21.3 30 , coding a protein with three exons and two gene promoters (P1 and P2). These two promoters have different functions in regulation of BCL2 expression, i.e., the P2 promoter is localized to the translation initiation site and functions as a negative regulatory element of the P1 promoter 31, 32 . Park et al. 33 identified BCL2-938C> A(rs2279115) in P2 and Nückel et al. 27 found that the -938C allele of BCL2-938C> A displayed a significant increase in BCL2 promoter activity. Concomitantly, expression of BCL2 protein in B-lymphocytes from chronic lymphocytic leukemia patients carrying the -938 AA genotype was significantly increased compared with CC genotypes. This has been confirmed by other studies of prostate cancer 34 , renal cancer 24 , oropharyngeal squamous cell carcinoma 35 and breast cancer 36 , although Zhang et al. 14 have an opposite result showing that the − 938A allele contributed to decreased expression of the BCL2 protein in breast cancer cell lines. Furthermore, previous studies showed that the BCL2-938 A variant was associated with a decreased risk of head and neck squamous cell carcinoma 11 and prostate cancer 13 , but increased risk of breast cancer 14 and glioma 16 . The -938 AA genotype was independently associated with worse PFS and OS of prostate cancer 34 , chronic lymphocytic leukemia 27 , glioblastoma multiforme 21 , and NSCLC
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, whereas it associated with a better prognosis of lymph node-negative invasive breast cancer 36 , oropharyngeal squamous cell carcinoma 35 , renal cancer 24 , ovarian cancer 37 , and limited-disease small cell lung cancer 38 . In our current study, we found that the BCL2-938 A variant was associated with poor PFS and OS of patients with advanced NSCLC after chemotherapy, which supports previous data reported by Katsuhiro Masago and colleagues of 168 advanced NSCLC patients who received platinum-based chemotherapy 20 . Expression of the anti-apoptotic BCL2 protein should contribute to resistance to cisplatin-induced tumor cell apoptosis and thus lead to a poor response and outcome. Indeed, BCL2 overexpression has been shown to be a marker of chemotherapy resistance in both SCLC and NSCLC 39, 40 . However, Fontanini et al. 41 reported that survival probability was higher in patients with BCL2-expressing, resected NSCLC because of the less aggressive behavior of NSCLC with BCL2 overexpression. A meta-analysis of 28 studies revealed that BCL2 overexpression had a positive influence on survival of NSCLC 42 . However, further study is needed to clarify this discrepancy.
BAX is localized to chromosome 19q13.3, coding a protein with six exons and a promoter 43 . The BAX promoter binds to different transcription factors or proteins, such as p53 response elements, the TATA box, canonical E-boxes, and the NF-κ B binding site to regulate BAX expression 44 . BAX was extensively studied in different types of cancer such as pancreatic cancer 45 , colon cancer 46, 47 , esophageal cancer 48 , lung cancer 49, 50 , squamous cell carcinoma of the head and neck 11 , prostate carcinoma 51 , ovarian carcinoma 52 , and breast cancer 53 . Recently, BAX-248G> A (rs4645878) was reported to be associated with reduced expression of BAX protein and altered susceptibility to chronic lymphocytic leukemia 25, 26 , although a meta-analysis of seven independent studies with 1772 cases and 1708 controls revealed that neither allele frequency nor genotype of BAX-248G> A associated with risk of human cancer using different genetic models 54 . Several studies reported that patients with BAX low expression had a significantly longer median survival in NSCLC 50 , esophageal squamous cell carcinoma 48 , and colon cancer 47 . Moreover, Paola Perego et al. 55 showed that p53 mutations developed cisplatin resistance in ovarian cancer as a consequence of the loss of p53 transactivation of BAX expression. Our current SNP data further confirm the role of BAX in the regulation of cisplatin resistance and shorter PFS and OS of patients with advanced NSCLC.
Indeed, previous studies showed that BAX was able to heterodimerize with BCL2 and Mcl-1 and that overexpression of BCL2 and Mcl-1 proteins compromised the proapoptotic capacity of BAX 56, 57 . Therefore, we determined to assess whether BCL2 and BAX interact synergistically to contribute to cisplatin resistance and alter the PFS and OS of patients with advanced NSCLC. We found that as the number of variant alleles increased, the median PFS and OS were decreased accordingly. Patients with more than 2 variant alleles had a much shorter median PFS and OS compared to those carrying 0-1 variant alleles.
Our current study is just the first of this kind for proof-of-principle. Although we showed that the BCL2-938C> A and BAX-248G> A SNPs significantly associated with platinum-based chemotherapy response, PFS and OS of patients with advanced NSCLC, we did not show the association of these SNPs with chemotherapy-related toxicities. However, the mechanism by which BCL2 SNPs may influence the clinical outcomes of patients with advanced NSCLC to platinum-based chemotherapy is unclear. This raises the question of whether a patient with such polymorphisms would have better survival than those without these polymorphisms in the absence of treatment. Do the polymorphisms actually affect the effectiveness of the regimen, or do they simply afford a better prognosis to patients? Hence, further work is necessary; for example, a larger sample size and a prospective study would be able to confirm our current data. Variation of BCL2 and BAX expression associates with an altered sensitivity and clinical outcome of NSCLC patients to chemotherapy.
